Takeda Pharmaceutical Files 6-K for September 2025

Ticker: TKPHF · Form: 6-K · Filed: Sep 8, 2025 · CIK: 1395064

Takeda Pharmaceutical Co Ltd 6-K Filing Summary
FieldDetail
CompanyTakeda Pharmaceutical Co Ltd (TKPHF)
Form Type6-K
Filed DateSep 8, 2025
Risk Levellow
Pages9
Reading Time11 min
Sentimentneutral

Sentiment: neutral

Topics: reporting, foreign-private-issuer

TL;DR

Takeda filed a 6-K on 9/8/25, confirming 20-F annual report filings.

AI Summary

Takeda Pharmaceutical Company Limited filed a Form 6-K on September 8, 2025, reporting information for the month of September 2025. The filing indicates Takeda is a foreign private issuer and will file its annual reports under Form 20-F.

Why It Matters

This filing serves as an update for investors regarding Takeda's ongoing reporting obligations as a foreign private issuer.

Risk Assessment

Risk Level: low — This is a routine administrative filing and does not contain new material financial or operational information.

Key Players & Entities

  • TAKEDA PHARMACEUTICAL CO LTD (company) — Filer
  • 0001395064-25-000130 (other) — Accession Number
  • 20250908 (date) — Filing Date
  • 001-38757 (other) — SEC File Number

FAQ

What type of report is Takeda Pharmaceutical filing?

Takeda Pharmaceutical is filing a Form 6-K, which is a Report of Foreign Private Issuer.

What is the filing date of this Form 6-K?

The filing date of this Form 6-K is September 8, 2025.

Under which form will Takeda file its annual reports?

Takeda indicates it will file its annual reports under Form 20-F.

What is Takeda Pharmaceutical's principal executive office address?

Takeda Pharmaceutical's principal executive office is located at 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo 103-8668, Japan.

What is Takeda's SIC code?

Takeda's Standard Industrial Classification (SIC) code is 2834, for Pharmaceutical Preparations.

Filing Stats: 2,828 words · 11 min read · ~9 pages · Grade level 14.7 · Accepted 2025-09-08 06:18:20

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date September 8, 2025 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025 SINGAPORE, OSAKA, Japan and CAMBRIDGE, Massachusetts, September 8, 2025 – Takeda (TSE4502NYSETAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861), a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), during multiple oral presentations at the World Sleep 2025 Congress in Singapore beginning at 315 p.m. SGT today. Please refer to the attached press release and presentation for details. The topline results of these studies were disclosed on July 14, 2025 in, "Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1". Media Contact Investor Contact Rachel Wallace r achel .wallace2takeda.com Christopher O'Reilly christopher.oreillytakeda.com Results from these studies have no significant impact on the full year consolidated forecast for the fiscal year ending March 31, 2026. ### Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025 – Takeda is the Leader in Orexin Science and is on Track to Submit Global Regulatory Applications Starting in Fiscal Year 2025 – Four Orexin Oral Presentations from Phase 3 Pivotal Studies Highlight Statistically Significant and Clinically Meaningful Improvement in Narcolepsy Type 1 Symptoms Demonstrating the Potential for a New Era of Care – Oveporexton was Generally Well-Tolerated with Safety Profile Consistent

Forward-Looking Statements

Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could", "anticipates", "estimates", "projects", "forecasts", "outlook" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States and with respect to international trade relations competitive pressures and developments changes to applicable laws and regulations, including tax, tariff and other trade-related rules challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof uncertainty of commercial success for new and existing products manufacturing difficulties or delays fluctuations in interest and currency exchange rates claims or concerns regarding the safety or efficacy of marketed products or product candidates the impact of health crises, like the novel coronavirus pandemic the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or o

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.